^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Trazimera (trastuzumab-qyyp)

    i
    Other names: PF-05280014, PF-5280014, PF 05280014, PF 5280014, PF05280014, PF5280014
    Company:
    Pfizer
    Drug class:
    HER2 inhibitor
    Related drugs:
    24h
    Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (clinicaltrials.gov)
    P2, N=20, Completed, University of Nebraska | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • cyclophosphamide • Trazimera (trastuzumab-qyyp)
    29d
    NCI-2016-00570: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 positive + HER-2 overexpression
    |
    Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp)
    1m
    Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, University of Washington | Trial primary completion date: Oct 2025 --> Aug 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    carboplatin • paclitaxel • docetaxel • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    1m
    HERTHENA-Breast-01: Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (clinicaltrials.gov)
    P1/2, N=81, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2029 --> Apr 2030 | Trial primary completion date: Sep 2029 --> Apr 2030
    Trial completion date • Trial primary completion date
    |
    Perjeta (pertuzumab) • Tukysa (tucatinib) • patritumab deruxtecan (U3-1402) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    2ms
    Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, University of Washington | N=16 --> 25
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    carboplatin • paclitaxel • docetaxel • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    2ms
    NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov)
    P2, N=6452, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Gilotrif (afatinib) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • sunitinib • Kadcyla (ado-trastuzumab emtansine) • Balversa (erdafitinib) • Mektovi (binimetinib) • adavosertib (AZD1775) • Truqap (capivasertib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • sapanisertib (CB-228) • ipatasertib (RG7440) • taselisib (GDC-0032) • omipalisib (GSK2126458) • ulixertinib (BVD-523) • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Paletan (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    4ms
    CALGB-40601: Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov)
    P3, N=305, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 amplification
    |
    paclitaxel • lapatinib • Trazimera (trastuzumab-qyyp)
    4ms
    Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=315, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    carboplatin • docetaxel • Trazimera (trastuzumab-qyyp) • goserelin acetate • Paletan (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    5ms
    Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=16, Recruiting, University of Washington | Trial primary completion date: Jun 2025 --> Oct 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    carboplatin • paclitaxel • docetaxel • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    5ms
    NCI-2016-00570: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2025 --> Oct 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 positive + HER-2 overexpression
    |
    Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp)
    6ms
    Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer (clinicaltrials.gov)
    P3, N=3270, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Trazimera (trastuzumab-qyyp)
    6ms
    Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy (clinicaltrials.gov)
    P3, N=2014, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Jun 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive
    |
    Trazimera (trastuzumab-qyyp)